USFDA Designates Indian Cytotron as a Breakthrough Device for Treatment of Liver, Pancreas and Breast Cancers

The Centre for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (US.FDA) has recently designated the Cytotron as a “Breakthrough Device” in the treatment of Cancer. Cytotron is an Indian Invented Medical Device, which aids in Tissue Engineering of Cancer cells to alter or modify how specific proteins are regulated to cause cancer cells to stop multiplying and spreading. Cytotron, generically known as Rotational Field Quantum Magnetic Resonance uses Fast Radio Bursts (FRB). Fast Radio Bursts are high energy and powerful short Radio bursts, in which both electric and magnetic components of the electromagnetic signals are “circularly” polarized. Fast Radio Bursts are produced when a radio signal is travelling through a powerful instantaneous magnetic field on its path to the target. FRBs can be used to communicate with the cellular command and control, to up or down regulate a specific protein or gene. In cancer cells, Cytotron does two things; first it alters the protein pathways of a pro-apoptosis protein called p53 via p21 thus inducing programmed cell death in the cancer cells, and secondly exposure to Cytotron stops metastasis by inhibiting the Epithelial Mesenchymal Transition cells, responsible for spread of cancer, 90% cancer patients die due to metastasis.  Over the years, Cytotron treatment for cancer has established 36%, 5 year survival and 73.3% with absence of metastasis in terminal cancer patients (Journal of Clinical and Experimental Oncology, 5:2, 2016). The results are far better in early cancer patients.

Cytotron was invented in India by the Indian Researcher, Dr. Rajah Vijay Kumar, at the Centre for Advanced Research and Development (CARD), after 27 years of research in understanding cellular pathways and interactions with specifically modulated fast radio bursts. “It is been a great feeling that after so many years of hard work against all odds, a prestigious institution like the USFDA is designating our work as a “breakthrough” in the treatment of Liver, Pancreas and Breast Cancers, three notorious ones”, said Dr. R. V. Kumar.

“The Cytotron is intended to be used to cause degeneration of uncontrolled growth of tissues. It is indicated for treating protein-linked, abnormally regenerating disorders such as Neoplastic disease, and allowing extended progression free survival, with pain relief, palliation, improved quality and dignity of life. It is indicated for the treatment of solid tumors of breast, Liver and Pancreas – We are pleased to Inform you that your device and proposed Indication for use meet the criteria and have been granted designation as a Breakthrough Device” said the communication from The Centre for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (US.FDA).